190 related articles for article (PubMed ID: 23382471)
1. Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.
Ehrlich PF; Anderson JR; Ritchey ML; Dome JS; Green DM; Grundy PE; Perlman EJ; Kalapurakal JA; Breslow NE; Shamberger RC
J Clin Oncol; 2013 Mar; 31(9):1196-201. PubMed ID: 23382471
[TBL] [Abstract][Full Text] [Related]
2. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
3. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database.
Saltzman AF; Carrasco A; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
J Pediatr Urol; 2018 Apr; 14(2):161.e1-161.e8. PubMed ID: 29133167
[TBL] [Abstract][Full Text] [Related]
4. Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5.
Kieran K; Anderson JR; Dome JS; Ehrlich PF; Ritchey ML; Shamberger RC; Perlman EJ; Green DM; Davidoff AM
J Pediatr Surg; 2012 Apr; 47(4):700-6. PubMed ID: 22498384
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
Breslow NE; Ou SS; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
Cancer; 2004 Sep; 101(5):1072-80. PubMed ID: 15329918
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting lymph node sampling patterns and the impact on survival of lymph node density in patients with Wilms tumor: a Surveillance, Epidemiology, and End Result (SEER) database review.
Walker JP; Johnson JS; Eguchi MM; Saltzman AF; Cockburn M; Cost NG
J Pediatr Urol; 2020 Feb; 16(1):81-88. PubMed ID: 31791906
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.
Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168
[TBL] [Abstract][Full Text] [Related]
11. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry.
Dávila Fajardo R; Oldenburger E; Rübe C; López-Yurda M; Pritchard-Jones K; Bergeron C; Graf N; van Grotel M; van Tinteren H; Saunders D; van den Heuvel-Eibrink MM; Janssens GO; Oldenburger F
Pediatr Blood Cancer; 2018 Aug; 65(8):e27085. PubMed ID: 29693799
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of event-free survival in patients with Wilms tumor undergoing preoperative chemotherapy. Analysis of lymph-node yield in a single-center cohort.
Flores P; Cadario M; Strambach J; Sanjuanelo M; Saleme JM; Paz E; Cacciavillano W; Felizzia G; Galluzzo L; Corbetta JP
J Pediatr Urol; 2021 Apr; 17(2):227.e1-227.e5. PubMed ID: 33309612
[TBL] [Abstract][Full Text] [Related]
15. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.
Shamberger RC; Guthrie KA; Ritchey ML; Haase GM; Takashima J; Beckwith JB; D'Angio GJ; Green DM; Breslow NE
Ann Surg; 1999 Feb; 229(2):292-7. PubMed ID: 10024113
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group.
Green DM; Breslow NE; D'Angio GJ; Malogolowkin MH; Ritchey ML; Evans AE; Beckwith JB; Perlman EJ; Shamberger RC; Peterson S; Grundy PE; Dome JS; Thomas PR; Kalapurakal JA
Pediatr Blood Cancer; 2014 Jan; 61(1):134-9. PubMed ID: 24038736
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
Benedetti DJ; Varela CR; Renfro LA; Tornwall B; Dix DB; Ehrlich PF; Glick RD; Kalapurakal J; Perlman E; Gratias E; Seibel NL; Geller JI; Khanna G; Malogolowkin M; Grundy P; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(6):947-961. PubMed ID: 37933882
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor: long-term results from a single institution.
Zaghloul MS; Hussein MH; el Koutbey M
J Surg Oncol; 1994 May; 56(1):25-31. PubMed ID: 8176938
[TBL] [Abstract][Full Text] [Related]
19. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
20. Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children's Oncology Group/National Wilms Tumor Study Group.
Ehrlich PF; Ferrer FA; Ritchey ML; Anderson JR; Green DM; Grundy PE; Dome JS; Kalapurakal JA; Perlman EJ; Shamberger RC
Ann Surg; 2009 Oct; 250(4):642-8. PubMed ID: 19730241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
